Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathee Till

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
The Prostate|November 26, 2009
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention TrialAlan R Kristal, Douglas K Price, Cathee Till, et al.
Cancer|March 13, 2019
Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202N Lynn Henry, Joseph M Unger, Cathee Till, et al.
Frontiers in Oncology|January 31, 2022
Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention TrialZhihong Gong, Mary E Platek, Cathee Till, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 6, 2009
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialElizabeth A Platz, Cathee Till, Phyllis J Goodman, et al.
JAMA Oncology|November 7, 2024
Long-Term Adverse Effects and Complications After Prostate Cancer TreatmentJoseph M Unger, Cathee Till, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Raphael P Viscidi, Cathee Till, et al.
Journal of the National Cancer Institute|August 28, 2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention TrialJoseph M Unger, Cathee Till, Ian M Thompson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 28, 2020
Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention TrialKathleen Torkko, Cathee Till, Catherine M Tangen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 25, 2010
Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention TrialAshraful Hoque, Christine B Ambrosone, Cathee Till, et al.
The Journal of Urology|January 15, 2013
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculatorDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
The Prostate|November 26, 2009
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention TrialAlan R Kristal, Douglas K Price, Cathee Till, et al.
Cancer|March 13, 2019
Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202N Lynn Henry, Joseph M Unger, Cathee Till, et al.
Frontiers in Oncology|January 31, 2022
Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention TrialZhihong Gong, Mary E Platek, Cathee Till, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 6, 2009
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialElizabeth A Platz, Cathee Till, Phyllis J Goodman, et al.
JAMA Oncology|November 7, 2024
Long-Term Adverse Effects and Complications After Prostate Cancer TreatmentJoseph M Unger, Cathee Till, Catherine M Tangen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Raphael P Viscidi, Cathee Till, et al.
Journal of the National Cancer Institute|August 28, 2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention TrialJoseph M Unger, Cathee Till, Ian M Thompson, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 28, 2020
Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention TrialKathleen Torkko, Cathee Till, Catherine M Tangen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 25, 2010
Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention TrialAshraful Hoque, Christine B Ambrosone, Cathee Till, et al.
The Journal of Urology|January 15, 2013
The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculatorDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 7